Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 14/20 | 0.44 |
| ▸ | CACNA1I | Q9P0X4 | 14/20 | 0.44 |
| ▸ | CACNA1H | O95180 | 13/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CLPP | Q16740 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14309433 | 0.89 | CACNA1G (0.41) | CACNA1GCACNA1ICACNA1HKMT2AMEN1 | |
| SCHEMBL14309426 | 0.89 | CLPP (0.51) | CLPPCYP3A4 | |
| SCHEMBL14319440 | 0.85 | CLPP (0.47) | CLPPCYP3A4 | |
| SCHEMBL14309878 | 0.85 | CTNNB1 (0.54) | CLPPCYP3A4 | |
| SCHEMBL13773538 | 0.85 | KMT2A (0.39) | CACNA1GCACNA1ICACNA1HKMT2AMEN1 | |
| SCHEMBL14309463 | 0.84 | KMT2A (0.41) | CACNA1GCACNA1ICACNA1HKMT2AMEN1 | |
| SCHEMBL14308269 | 0.84 | CLPP (0.47) | CACNA1ICLPPCYP3A4 | |
| SCHEMBL14309451 | 0.84 | CLPP (0.47) | KMT2AMEN1CLPPCYP3A4 | |
| SCHEMBL14310175 | 0.84 | CACNA1I (0.42) | CACNA1GCACNA1ICACNA1HKMT2AMEN1 | |
| SCHEMBL14310108 | 0.82 | HDAC1 (0.39) | CACNA1GCACNA1ICACNA1HKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070129353-A1 | Alpha-helix mimetics and method relating to the treatment of cancer stem cells | INSTITUTE FOR CHEMICAL GENOMICS | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129353-A1 | Alpha-helix mimetics and method relating to the treatment of cancer stem cells | MCL1, HNF4A, THPO | CACNA1G 4680/4885CACNA1I 4831/4885CACNA1H 4289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.